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Introduction. To analyze patients with atypical squamous cells of undetermined signiﬁcance (ASCUS) through a cytology review
and the presence of microbiological agents, with consideration of colposcopy and semiannual tracking. Methods. 103 women with
ASCUS were reviewed and reclassiﬁed: normal/inﬂammatory, ASCUS, low-grade squamous intraepithelial lesion (LSIL), or high-
grade squamous intraepithelial lesion (HSIL). If ASCUS conﬁrmed, it was subclassiﬁed in reactive or neoplastic ASCUS, ASC-US,
or ASC-H; and Regione Emilia Romagna Screening Protocol. Patients underwent a colposcopic examination, and test for Candida
sp., bacterial vaginosis, Trichomonas vaginalis, and human papillomavirus (HPV) were performed. Results. Upon review, ASCUS
was diagnosis in 70/103 (67.9%), being 38 (54.2%) reactive ASCUS and 32 (45.71%) neoplastic ASCUS; 62 (88.5%) ASC-US and
8 (11.41%) ASC-H. ASCUS (Regione Protocol), respectively 1-5: 15 (21.4%), 19 (27.1%), 3 (27.1%), 16 (22.8%), and 1 (1.4%). A
higher number of cases of cervical intraepithelial neoplasia (CIN) II/III in the biopsies of patients with ASC-H compared to ASC-
US (P = .0021). High-risk HPV test and presence of CIN II/III are more frequent in ASC-H than ASC-US (P = .031). Conclusions.
ASC-H is associated with clinically signiﬁcant disease. High-risk HPV-positive status in the triage for colposcopy of patients with
ASC-US is associated with increased of CIN.
1.Introduction
Since Papanicolaou’s introduction of the Pap smear (1943),
a variety of terms have been used to describe accompa-
nying cytological diagnoses [1]. The Bethesda classiﬁcation
proposed in 1988 (revised in 1991) reﬂects the biological
behavior of squamous intraepithelial lesions (SILS) of the
cervix [2]. This classiﬁcation scheme subdivides abnormal
squamous epithelial cells into four groups: (1) atypical squa-
mous cells of undermined signiﬁcance (ASCUS); (2) low-
grade squamous intraepithelial lesions (LSILS), encompass-
ing light dysplasia/cervical intraepithelial neoplasia (CIN)
I as well as cell changes associated with the human papil-
lomavirus (HPV); (3) high-grade squamous intraepithelial
lesions (HSIL), including moderate dysplasia/CIN II, severe
dysplasia, and carcinoma in situ/CIN III; (4) squamous cell
carcinoma.
The ASCUS diagnosis has caused confusion and contro-
versy with respect to its signiﬁcance and appropriate use [3–
5]. More than 2 million women in the United States receive
a diagnosis of ASCUS in cervical-vaginal cytology each year
[4–6]. The ideal clinical tracking of these women has been
highly controversial, and doubts remain regarding which
control and treatment strategies are best [3, 7].
Comparisons between laboratories have shown that the
diagnostic frequency of ASCUS varies from 1.6% to 9%
[8, 9]. Gerber et al. detected ASCUS in 5% (1,387) out of a
total of 29,827 patients in their study [9]. Lee et al. reported
1,035 ASCUS diagnoses out of 49,882 oncological cytologies
p e r f o r m e d ,a2 %f r e q u e n c yr a t e[ 10]. According to some2 Infectious Diseases in Obstetrics and Gynecology
authors, the frequency of ASCUS should not exceed 2- to -3
times the frequency of LSIL [2–11].
Guerrinietal.haveattemptedtobetterdeﬁnetheASCUS
diagnosis by using the morphological criteria recommended
by the Regione Emilia Romagna Screening Protocol (1997)
[12]. This subdivision improved treatment courses, as cases
of ASCUS at levels 1 to 3 corresponded to more substantial
colposcopicﬁndingswhicharerelatedtothepresenceofCIN
in biopsies [13].
The new Bethesda reclassiﬁcation released in 2001
included a major change with respect to ASCUS. The cate-
gory was subdivided into two categories: ASC-US (atypical
squamous cells of undetermined signiﬁcance), which reﬂects
the diﬃculties in distinguishing between reactive changes
and LSIL, and ASC-H (atypical squamous cells, cannot
rule out a high-grade lesion), which reﬂects a diﬀerential
diagnosis between immature reactive metaplasia and HSIL
[10,14].Morinetal.showedthepresenceofCINin22.2%of
the biopsies of 360 women with ASCUS, with 16.1% having
CIN I and 5.3% having CIN II/III [1].
Research on HPV has begun to shape part of the
evaluation of patients with ASCUS and other cytological
changes [15]. The addition of a biomolecular test for HPV
increases the sensitivity of detection for CIN in women with
ASCUS relative to repeated cytology [16]. On the other
hand, a negative test for HPV in women with ASCUS can
reduce the number of times colposcopy is needed and reduce
unnecessary biopsies [1, 17]. The HART (HPV Testing in
Addition to Routine Testing Study), HPV testing with reﬂex
results, was found to be highly sensitive for the diagnosis
of subjacent CIN in women between the ages of 30 and 60,
compared to a repetition of cytology [18].
The correct interpretation of the intensity of ASCUS
morphological changes with respect to patient prognosis,
the signiﬁcance of the ﬁndings, and the appropriate clinical
course to be followed have yet to be clariﬁed. Therefore, the
objectives of this study were (1) to evaluate the variation
in the ASCUS diagnosis in routine Papanicolaou exams and
other morphological classiﬁcations of ASCUS, (2) to analyze
the microbiological agents that cause inﬂammation, and (3)
to evaluate the use of HPV testing in the triage of patients
with ASCUS based on colposcopy.
2.MaterialsandMethods
2.1. Study Design. A prospective study was performed at the
walk-in clinic of the Gynecology and Obstetrics Division
of the Federal University of the Triˆ angulo Mineiro between
January 2003 and December 2007. In the ﬁrst part of the
study, women with a diagnosis of ASCUS were evaluated by
cervical-vaginal cytology in a routine exam performed by
four medical cytopathologists. Cytology ﬁndings were used
in triage, and the order of patient entry followed the series
sequence of the Pap smear registrations of the institution’s
cytopathology service.
Patients with a diagnosis of ASCUS, who were taken to
the colposcopy service, were informed about the study and
its purpose. Those who agreed to participate signed terms of
informed consent approved by the ethics committee of the
Federal University of the Triˆ angulo Mineiro. Women became
part of the study when they met the inclusion criteria: a
diagnosis of ASCUS by cytology; not pregnant; no bleeding
during the exam; no use of oral antibiotics, fungicides, or
vaginal creams in the last 30 days; sexual abstinence for
at least two days; no previous history of SIL or cervical
procedures.
2.2. Methods
2.2.1. Clinical Methods. Information about the age, habits,
and lifestyles (parity, number of partners, age of sexarche,
age of ﬁrst pregnancy, and smoking status), contraceptive
methods used, and history of sexually transmitted diseases
was initially collected.
2.2.2. Microbiological and Biochemical Methods. After pro-
vidingtheabovedata,thepatientsunderwentagynecological
examination, colposcopy, and collection of cervical-vaginal
material for the study of microbiological agents and HPV
by the hybrid capture technique. A variety of procedures
were used to collect the samples as described hereafter.
To search for Trichomonas vaginalis, material was collected
from the base of the vaginal fornix with a swab, and the
secretion was placed on a glass slide. After adding drops
of saline solution and placing a coverslip on the specimen,
a search for moving and ﬂagellated microorganisms was
performed by optical microscopy (fresh examination). To
search for Candida sp., vaginal material was collected with
a swab and seeding performed in a Petri dish, containing
the Sabouraud Agar culture medium, where the growth of
fungus was veriﬁed. To search for bacterial vaginosis, the
widelyacceptedclinicalcriteriaoriginallyproposedbyAmsel
et al. were used [19]: (1) homogenous vaginal secretion that
adheres to the vaginal walls, (2) vaginal pH above 4.5, (3) the
presence of a characteristic smell after adding a solution of
10% potassium hydroxide to the vaginal secretion, and (4)
the presence of “clue cells” in the Gram-colored smear. The
presence of 3 out of 4 of the above criteria was considered
suﬃcient for establishing a diagnosis. Measurement of pH
was performed by collecting vaginal material using a swab
and then introducing it into a sterile test tube, containing
1mL of distilled, deionized water. The material was taken
to the laboratory at the end of the consult, and vaginal
pH was gauged using a designated digital Sentron brand
pH meter, which uses a 0 to 14pH scale [20]. For this
determination, the contents of the test tube were used.
After homogenization in a vortex for about 10seconds, the
swab was removed and introduced into the ﬂask of the pH
measuring machine, with an electrode located at its end.
Quantiﬁcation of pH was done digitally on the spot. This
proceduretookplacenolongerthan1houraftereachsample
had been collected. To search for human HPV, endocervical
and ectocervical material was initially collected with a special
brush, a component of the Digene hybrid capture kit, and
placed in its own tube containing material to preserve it,
and then maintained frozen at a temperature of −20◦C.Infectious Diseases in Obstetrics and Gynecology 3
At the end of the collection period, once a suﬃcient number
of samples had been obtained, the tubes were defrosted and
analyzed according to hybrid capture techniques.
Hybrid Capture. The Hybrid Capture II System DML 2000
brand microplate system machine with signal ampliﬁca-
tion was used for chemiluminescence. The information
and methodology described below were derived from the
instruction manual provided by the product vendor (Digene
of Brazil) and are consistent with previously described
techniques [20].
The kit used to detect HPV had 18 viral types grouped
into two pools of probes. The probes for low-risk virus
included types 6, 11, 42, 43, and 44, representing approxi-
mately 70% of this viral group. With respect to the high-risk
virus, the system had probes for types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, and 68, representing approximately
99% of this viral group. According to the vendor, the mi-
croplating sensitivity for HPV is 1pg/mL, equivalent to 0.1
copies of the virus.
Colposcopic Exam. After the materials had been collected,
the patients underwent video-colposcopy with image cap-
ture. The Barcelona classiﬁcation scheme [21], proposed in
2002, was used to describe the ﬁndings. Brieﬂy, samples
were divided into two classes: normal colposcopic ﬁndings
(original squamous epithelium, columnar epithelium, and
normal transformation zone) and abnormal colposcopic
ﬁndings (acetowhite epithelium, spotted, mosaic, leucopla-
sia, iodine-negative zone, and atypical vessels), with the
latter category subdivided into minor or major changes
depending on the intensity of the changes observed. The
following reagents were used to perform the colposcopy:
aqueous solution of 3% glacial acetic acid, lugol’s solution,
and sodium bisulﬁte. When changes were observed, the
patients subsequently underwent a directed biopsy using
Gaylor-Medina forceps.
Cytological Evaluation and Histopathology. In a second step,
the smears of patients with an initial diagnosis of ASCUS by
the cytopathologists during the routine exam were reviewed
and reclassiﬁed by the same cytopathologists, in collabora-
tion with the author of this study, as normal/inﬂammatory
cytology,ASCUS,LSIL,orHSIL.WhenadiagnosisofASCUS
was conﬁrmed upon review, the case was subclassiﬁed as
either probably reactive or probably neoplastic (Bethesda
1988–1991) and, also according to the Bethesda 2001 norms,
as ASC-US or ASC-H. Cases of ASCUS were newly subclassi-
ﬁed according to their morphological changes following the
recommendations of the Regione Emilia Romagna Screening
Protocol [12] into the following groups: atypical squamous
cells with mature-intermediate type cytoplasm (ASCUS 1),
metaplastic atypical squamous cells (ASCUS 2), atypical
squamous cells with parakeratosis (ASCUS 3), reactive
atypical cells (ASCUS 4), and atypical squamous cells with
atrophy (ASCUS 5).
The cytology smear was colored using the Papanicolaou
technique and evaluated according to the morphologi-
cal criteria of amphophilia, perinuclear halo, dyskeratosis,
nuclear criteria (binucleation, multinucleation), increase in
thenucleus/cytoplasmrelation,anisokaryosis,hyperchroma-
sia, nuclear atypias, and karyorrhexis. The biopsies were
also reviewed and reclassiﬁed by the same pathologist, in
conjunction with the author of this study. The patients
underwent new cytological and colposcopic evaluations after
6 months. The results were analyzed by comparing cytologi-
cal and colposcopic criteria, the presence of microbiological
agents that cause infection and HPV in patients with ASCUS
of a probably reactive character and ASCUS of a probably
dysplastic character, ASC-US, and ASC-H.
2.2.3. Statistical Analysis. The GraphPad InStat program,
version 3.0, was used for statistical analysis. The results were
compared using Fisher’s exact test with a signiﬁcance level of
less than 5% (P<. 05).
3. Results
Between January 1, 2003, and December 31, 2007, 46,362
Pap smears were performed by the cytopathology service of
the Gynecology and Obstetrics Division. Of these, 41,349
(89.18%) had a negative cytology for oncological changes,
2,309 (4.98%) had a diagnosis of ASCUS, 265 (0.57%)
had a diagnosis of AGUS (atypical glandular changes of an
undermined signiﬁcance), 1,760 (3.79%) had a diagnosis of
LSIL, 551 (1.18%) of CIN II/III, and 128 (0.27%) of invasive
carcinoma of the cervix. The screening is opportunistic and
covers some areas of Uberaba (Minas Gerais, Brazil) and
some neighboring towns. The population served is of low
socioeconomic status.
A total of 103 women with an initial diagnosis of ASCUS
were randomly selected and evaluated. Their average age
was 35.76 (range, 18–50 years old). Of the 103 participants,
32 (31%) were smokers. In terms of contraceptive use, 40
(38.83%) had received tubal ligation, 30 (29.12%) used hor-
monal methods, 3 (2.91%) used only condoms, 1 (0.97%)
used an intrauterine device, and 29 (28.15%) did not use
any form of contraceptive. The women’s average number of
sexual partners was 2.15 (range, 1–10). The average age of
their ﬁrst sexual relationships was 17.62 years old (range,
12–27 years old) and the average age of their ﬁrst pregnancy
was 19.67 years old (range, 12–31 years old). Sixteen women
(15.53%) were nulliparous, 60 (58.25%) had between one
and three children, and 27 (26.21%) had more than three
children.
The slides of all 103 of these initial cases of ASCUS
were reviewed by the same examiner in conjunction with
the author of this study, evaluating a variety of changes
according to the protocol. Of the 103 cases, 70 (67.96%)
wereconﬁrmedasASCUSatthesecondreading;30(29.12%)
were reclassiﬁed as normal/inﬂammatory smears, 2 (1.94%)
asLSIL,and1(0.97%)asHSIL.Ofthe70casesofASCUS,38
(54.28%) were reclassiﬁed as ASCUS of a probably reactive
nature and 32 (45.71%) as ASCUS of a probable neoplastic
nature (Bethesda, 1991); 62 (88.57%) were reclassiﬁed as
ASC-USand8(11.41%)asASC-H(Bethesda,2001).Patients4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Distribution of patients with an initial diagnosis of ASCUS which, upon review, were reclassiﬁed as normal/inﬂammatory, ASCUS
of a probably reactive nature, and ASCUS of a probably neoplastic nature, in relation to infection.
Cytology
Agent Normal/inﬂammatory N(%) ASCUS
Probably reactive N(%) Probably neoplastic N(%) ASC-US N(%) ASC-H N (%)
Candida sp. 4 (13.4) 9 (23.6) 4 (12.5) 13 (21) 0
Bacterial vaginosis 2 (6.6) 6 (15.8) 6 (18.7) 12 (19.3) 0
Trichomonas vaginalis 0 2 (5.2) 0 2 (3.2) 0
No infection 24 (80.0) 21 (55.2) 22 (68.7) 35 (56.4) 8 (100)
Total cases by group 30 38 32 62∗ 8
∗P = .0196 versus ASC-H, Fisher’s exact test.
Table 2: Principal colposcopic ﬁndings in patients with an initial diagnosis of ASCUS who, upon review, were reclassiﬁed as normal/inﬂam-
matory cytology, probably reactive ASCUS, probably neoplastic ASCUS, ASC-US, and ASC-H.
Cytology
Colposcopy Normal/inﬂammatory N (%) ASCUS
Probably reactive
N (%)
Probably neoplastic
N (%)
ASC-US N
(%)
ASC-H
N (%)
Normal ﬁndings 17 (56.6) 23 (60.5) 9 (28.1) 32 (51.6) 0
Abnormal ﬁndings
Major∗ 0 0 6 (18.7)∗ 1 (1.6) 5 (62.5)∗∗
Minor 8 (26.6) 9 (23.6) 15 (46.8) 21 (33.9) 3 (37.5)
Unsatisfactory 5 (16.6) 6 (15.8) 2 (6.2) 8 (12.9) 0
Total cases by group 30 38 32 62 8
∗P = .0020 and P = .0018 for the presence of abnormal and major abnormal colposcopic ﬁndings, respectively, versus the probably reactive ASCUS group,
Fisher’s exact test.
∗∗P = .0017 and P<. 0001 for the presence of abnormal and major abnormal colposcopic ﬁndings, respectively, versus the ASC-US group, Fisher’s exact
test.
with a diagnosis of SIL at the review were excluded from the
reporting of the results.
The results of the microbiological examinations for
Candida sp., bacterial vaginosis. and T. vaginalis of 100
of the patients reevaluated in this study are shown in
Table 1. No statistically signiﬁcant diﬀerence was found
in the comparison of the presence of infection (bacterial
vaginosis, Candida sp. and T. vaginalis) between the group
with probable reactive ASCUS and probable neoplastic
ASCUS. A statistically signiﬁcant diﬀerence was observed,
however, with respect to the presence of infection between
the ASCU-US and ASC-H groups.
The colposcopic ﬁndings are shown in Table 2. The col-
poscopy was considered unsatisfactory when it was not
possible to see the squamocolumnar junction. When com-
paring the presence of abnormal colposcopic ﬁndings in
the probably reactive and probably neoplastic groups, a
statistically signiﬁcant diﬀerence was found, with more
abnormal ﬁndings being observed in the neoplastic group.
When the same groups were compared, but only major
colposcopic ﬁndings were evaluated, the diﬀerence remained
signiﬁcant, being greater in the group with changes that were
probably neoplastic. Analysis of the colposcopic ﬁndings
in the patients with cytology reviewed according to the
Bethesda 2001 classiﬁcation revealed signiﬁcantly more
abnormal colposcopic ﬁndings in the ASC-H group than in
the ASC-US group. A similar comparison for major colpo-
scopic ﬁndings also revealed signiﬁcantly more incidences in
the ASC-H group relative to the ASC-US group.
Amongthe70patientswithASCUSaftercytologyreview,
30 (42.8%) underwent biopsy. Five of these (16.6%) were
infected with HPV, 9 (30%) had CIN (3 CIN I, 3 CIN
II and 3 CIN III), and 16 (53.3%) had normal biopsies.
HPV infection was present in 4 patients with probable
neoplastic ASCUS and in 1 patient with probable reactive
ASCUS; in the Bethesda 2001 classiﬁcation, the 5 HPV cases
all involved patients with ASC-US that were subjected to
biopsies. Three cases of CIN I were present in biopsies of
patients with probable reactive ASCUS (Bethesda 1991) and
ASC-US (Bethesda 2001). CIN II was present in 1 patient
with reactive ASCUS and 2 with probable neoplastic ASCUS;
and in the 2001 classiﬁcation, all cases of CIN II were
present in the biopsies of patients with ASC-H. All three
CIN III diagnoses were made in patients in the neoplastic
ASCUS and ASC-H groups. In the group of 30 patients
with normal/inﬂammatory cytology, 8 underwent biopsy,
revealing CIN I in 1 case and HPV infection in 1 case.
The anatomopathological results of biopsies performed
in patients with changes found during the colposcopic
examination are shown in Table 3. No statistically signiﬁ-
cant diﬀerences were found when the presence of changes
was compared between the normal/inﬂammatory, probablyInfectious Diseases in Obstetrics and Gynecology 5
Table 3: Results of biopsies performed on patients with an initial diagnosis of ASCUS who, upon review, were reclassiﬁed as having
normal/inﬂammatory cytology, probably reactive ASCUS, and probably neoplastic ASCUS, and who, in accordance with the Regione Emilia
Romagna (ASCUS 1 to 5), showed evidence of changes in the colposcopic exam.
Cytology
Biopsy Normal/inﬂammatory N (%) ASCUS
Probably reactive
N (%)
Probably neoplastic
N (%)
1 N (%) 2 N (%) 3 N (%) 4 N (%) 5 N (%)
Normal 6 (20.0) 7 (18.4) 9 (28.1) 1 (6.6) 5 (26.3) 5 (26.3) 4 (25.0) 1 (100.0)
HPV/CINI 2 (6.6) 1 (2.6) 7 (21.8) 2 (13.3) 4 (21.0) 2 (10.5) 0 0
CIN II/III 0 1 (2.6) 5 (15.6) 3 (20.0) 2 (10.5) 0 1 (6.25) 0
Not performed 22 (73.3) 29 (76.3) 11 (34.3) 9 (60.0) 8 (42.1) 12 (63.1) 11 (68.7) 0
Total cases by group 30 38 32 15 19 19 16 1
All Ps >. 05; Fisher’s exact test.
Table 4: Results of the biopsies performed on the total group of patients with an initial diagnosis of ASCUS who, after review,
were reclassiﬁed as having cytologies that were normal/inﬂammatory, ASC-US, and ASC-H, which showed changes in the colposcopic
examination.
Cytology
Biopsy Normal/inﬂammatory N (%) ASCUS
ASC-US N (%) ASC-H N (%)
Normal 6 (20.0) 13 (21.0) 3 (37.5)
HPV/CIN I 2 (6.6) 8 (13.0) 0
CIN II/III 0 1 (1.6) 5 (62.5)∗
Not performed 22 (73.3) 40 (64.5) 0
Total cases by group 30 62 8
∗P = .0256 and P = .0021, relative to ASC-US group, versus ASC-H group with normal/inﬂammatory cytology and cases of CIN II/III in biopsies of patients
with ASC-H, respectively, Fisher’s exact test.
reactive ASCUS, and probably neoplastic ASCUS groups.
The reconﬁrmed cases of ASCUS (n = 70) were then
subclassiﬁed according to the recommendations of the
Regione Emilia Romagna Screening Protocol as follows: 15
cases of ASCUS 1 (21.4%), 19 of ASCUS 2 (27.1%), 19
of ASCUS 3 (27.1%), 16 of ASCUS 4 (22.8%), and 1 case
of ASCUS 5 (1.42%). The results of the biopsies showed 3
cases of CIN II/III among patients with ASCUS 1, 2 cases
among patients with ASCUS 2, and 1 case among patients
with ASCUS 4. There were no cases of CIN II/III among
the patients with ASCUS 3 and 5. When the results of the
colposcopic ﬁndings as classiﬁed according to the Regione
Emilia Romagna were analyzed, there were no statistically
signiﬁcant group diﬀerences.
When the results of the biopsies were reevaluated against
the cytologies according to Bethesda 2001 (Table 4), we
found a greater frequency of CIN II/III in the group of
patients with ASC-H, compared to the group with normal/
inﬂammatory cytology. There were a greater number of
cases of CIN II/III in the biopsies of patients with ASC-
H relative to the group with ASC-US. When CIN II/III
ﬁndings were compared between the morphological ASCUS
groups, we found a signiﬁcantly greater frequency among
patients with ASC-H than those with ASCUS 1 and those
withprobableneoplasticASCUS.Thedistributionofcasesof
CIN II/III (absent/present – n, %) at biopsy in relation to the
cytologicaldiagnosesofprobablyneoplasticASCUS,ASC-H,
and ASCUS 1 (Regione Emilia Romagna Classiﬁcation)
showed 27/5 (84.3%/15.6), 12/5 (80/20), and 3/5 (37.5/62.5),
respectively, Bethesda 1991, probably neoplastic ASCUS,
Regione Emilia Romagna, ASCUS 1 and Bethesda 2001,
ASC-H, being P = .0713 and P = .0145, respectively,
Bethesda 2001, ASC-H versus ASCUS 1 and probably neo-
plastic ASCUS (Fisher’s exact test).
With regard to the hybrid capture test in the 100 cases
with an initial diagnosis of ASCUS, the presence of high-
risk HPV DNA was detected in 19 (27.1%) women with
reconﬁrmed ASCUS and in 8 (26.6%) with normal cytology
on review. There was a greater frequency of high-risk
HPV infection in the ASC-H group compared to the ASC-
US group. The results of DNA/high-risk HPV experiment
(negative/high-risk HPV – n, %) using the hybrid capture
techniqueinpatientswithaninitialdiagnosisofASCUSwho,
upon review, were reclassiﬁed as having cytologies that were
normal/inﬂammatory, ASC-US and ASC-H showed 22/8
(73.3/26.6), 48/14 (77.4/22.6), 3/5 (37.5/62.5), respectively,
normal, ASC-US, and ASC-H cytologies, being P = .0296,
ASC-H versus ASC-US for high-risk HPV (Fisher’s exact
test). Of the 6 cases of high-grade CIN, after a biopsy guided
by colposcopy (out of the 100 cases evaluated in the study),
5 (83.3%) tested positive for high-risk HPV by the hybrid
capture technique. Table 5 shows the correlations between
ASC-US,ASC-H,andnormal/inﬂammatorybiopsiesandthe
presence of high-risk HPV and the biopsy of high-grade6 Infectious Diseases in Obstetrics and Gynecology
Table 5: Presence of CIN II/III in biopsies, in relation to positivity for high-risk HPV through hybrid capture, and reclassiﬁcation of ASCUS
cytology according to Bethesda 2001.
Cytology
High-risk HPV positive High-risk HPV negative
Biopsy with CIN
II/III N (%)
Biopsy without
CIN II/III
N (%)
Biopsy not
performed
N (%)
Biopsy with
CIN II/III
N (%)
Biopsy without
CIN II/III
N (%)
Biopsy not
performed N (%)
ASC-US 1 (20.0) 7 (70.0) 6 (50.0) 0 14 (63.6) 34 (68.0)
ASC-H 4 (80.0)∗ 1 (10.0) 0 1 (100.0) 2 (9.0) 0
Normal 0 2 (20.0) 6 (50.0) 0 6 (27.3) 16 (32.0)
Total 51 0 1 212 2 5 0
∗P = .0319, presence of CIN II/III at biopsy versus ASC-US among patients who tested positive for high-risk HPV, Fisher’s exact test.
lesions. We found a greater proportion of CIN II/III in the
biopsies of patients testing positive for high-risk HPV in the
ASC-H group than in the ASC-US group.
Out of a total of 70 patients with a diagnosis of
ASCUS, after review, 6 were transferred to the oncology
service for treatment because of biopsies showing CIN II
or III. Of the 64 remaining cases, 7 did not come for
followups. Of the 57 patients diagnosed with ASCUS, 43
had normal/inﬂammatory cytology and normal colposcopy
at their semi-annual followup, 7 had ASC-US and normal
colposcopy, and 7 had LSIL (4 CIN I and 3 HPV; with all
cases of CIN I being proven by directed biopsy). Of these, all
casesofCINIandIIwerediagnosedintheﬁrstbiopsy.Ofthe
4 cases of CIN I, 3 came from the initial group with probable
neoplastic ASCUS and 1 came from the probably reactive
ASCUS group. Based on the 2001 classiﬁcation, all CIN I
cases belonged to the ASC-US group. Of the 3 patients with
HPV, 1 came from the initial probably neoplastic ASCUS
group and 2 came from the probably reactive group; all 3
belonged to the ASC-US group.
Of the 30 patients for whom the diagnosis of ASCUS was
not conﬁrmed upon cytological reclassiﬁcation, no tracking
was performed. At their semi-annual followups, 25 (83.3%)
had normal colposcopic exams and normal/inﬂammatory
cytology and 3 had ASC-US. There were no cases of
CIN in semesterly tracking in patients who had a nor-
mal/inﬂammatory cytology diagnosis on reclassiﬁcation.
4. Discussion
A diagnosis of ASCUS not only depends on well-deﬁned
cytological patterns, but also on many subjective criteria
[6, 12]. The reproduction of the interpretation of ASCUS
is lower than 50% [6]. We observed that the number of
cytologicaldiagnosesofASCUSinourservicewasequivalent
to 1.3× the frequency of LSIS, or 4.98% of all cytologies
performed. ASCUS frequency rates in the literature vary
from 2% to 7% [10, 22, 23]. The present results from our
service demonstrate an ASCUS frequency compatible with
the Bethesda expectations.
In the women with a conﬁrmed diagnosis of ASCUS,
altered biopsies were found in 20% of the cases, with 11.4%
of these being HPV/CIN I and 8.6% being CIN II/III. Some
studies have reported a concomitance of CIN II/III in 5–
10% of patients with ASCUS [1], results similar to those
from our study. Roche and Spicer, who tracked patients with
ASCUS for 2 years, reported 18% of cases with HPV/CIN
I and 15% with CIN II/III [24]. Eltabbakh et al. found a
15.9%frequencyofneoplasiainpatientswithASCUS[25].A
priorstudyperformedbyourgroupevaluating1,244women
with ASCUS revealed CIN I in 60.3%, CIN II/III in 17.46%,
and invasive neoplasia in 6.3% of the cases [26]. Thus it was
concluded that CIN or invasive lesions can occur in women
with ASCUS, and therefore new cytology or colposcopy and
rigorous tracking should be considered for these patients.
All patients in our study with a diagnosis of ASCUS,
upon review, were reclassiﬁed as having lesions of a probable
neoplastic nature (45.7%) or of a probable reactive nature
(54.2%), a result quite similar to previous work by our group
(45.4% probable neoplastic ASCUS and 54.5% probable
reactive ASCUS after reviewing the ASCUS cytologies)
[13]. Other studies in the literature have also made this
subdivision. Guerrini et al. reclassiﬁed 107 patients with a
diagnosisofASCUSandfound78.5%ofthemtobeprobably
reactive and 21.5% to be probably neoplastic [12]. The
absence of well-deﬁned criteria, as well as the subjectivity
of the diagnosis, may account for this variation. After
reclassiﬁcation according to the Regione Emilia Romagna,
our ﬁndings showed the presence of CIN II/III in 20% of
the ASCUS 1 cases, 10.5% of the ASCUS 2 cases, 1% of the
ASCUS 4 cases, and none of the ASCUS 3 and 5 cases. We
observed a higher frequency of CIN II/III in the biopsies of
patients with ASCUS 1, a ﬁnding similar to that of Guerrini
et al. [12].
Women with a cytological diagnosis of ASC-H have been
showntohaveahigherassociationwithCINII/IIIthanthose
with ASC-US [14]. Barreth et al. studied 517 women with a
cytology of ASC-H, and found a 2.9% presence of cervical
cancer, 1.7% with in situ adenocarcinoma, and 65.6% with
CIN II/III [27]. In another study, 85 women with ASC-H
underwent colposcopies and histological analysis of biopsies
of the areas of change, with CIN II and III being found in
52 (61.2%) of the cases and invasive cancer being found in
7 (8.2%) of the cases [28]. Similar results were found in our
study,whichveriﬁedlevelsof62.6%ofCINII/IIIforpatients
classiﬁed as ASC-H. The diagnosis of ASC-H in the Papani-
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disease, and a biopsy directed by colposcopy should be con-
sidered the proper course of action in these cases.
We performed a comparison of the Bethesda 1991,
Bethesda 2001, and Regione Emilia Romagna classiﬁcations
to better diagnose CIN II/III. We did not ﬁnd any prior
studies in the literature that had compared these three clas-
siﬁcation systems. When we performed the analysis, we
observed a higher frequency of CIN II/III in cases of ASC-
H than in cases of probable neoplastic ASCUS and ASCUS
1. Nevertheless, a limitation of our study is a low number of
CIN II/III cases.
The detection of high-risk HPV DNA is thought to
be useful in supplementing an abnormal cytological result
[29, 30] and that in women with ASCUS, the presence of an
HPV-positive group can substantially increase the chances of
ﬁnding CIN II/III and cervical cancer, even though in the
majority of these women signiﬁcant lesions are not found
[6]. Therefore, some authors recommend that testing for
HPV DNA be performed on women with ASCUS [15, 31],
while a biopsy guided by colposcopy is only recommended
if high-risk HPV is present, while other women are treated
more conservatively [5].
Various studies have shown a diﬀerence in the presence
of HPV DNA when the cytologies of ASC-US and ASC-H
are compared. Srodon et al. studied patients with ASCUS
classiﬁed according to the Bethesda 2001 system and found
HPV to be present in 67% of women with ASC-H and 45%
of women with ASC-US [32]. In evaluating the presence
of high-risk HPV by hybrid capture, Kurman and Solomon
found it to be present in 14.2% of ASC-US cases and 66.6%
of ASC-H cases [2]. In our study, we found high-risk HPV
in 22.5% of patients with ASC-US and 62.5% of patients
with ASC-H. When the cytologies of ASC-US and ASC-H
were compared, the presence of high-risk HPV DNA was
statistically greater in the latter, highlighting the importance
of this division in the detection of clinically signiﬁcant
disease.
Srodon et al. evaluated the presence of HPV and high-
grade CIN in patients with ASC-US and ASC-H and found
CIN II/III in 10.2% of HPV-positive patients with ASC-US
and in 5.9% of HPV-negative patients with ASC-US [32].
We found that 7.14% of the cases of high-grade CIN II/III
were in HPV-positive women with ASC-US. Furthermore,
we found higher rates of CIN II/III in HPV-positive patients
with ASC-US than in HPV-negative ASC-US group (no
cases of high-grade CIN). The presence of CIN II/III in
7.14% of the HPV-positive women with ASC-US suggests
that the HPV test could be used in the triage of patients
with ASC-US for a colposcopy and that HPV positivity
may be associated with an increased probability of CIN.
The diagnosis of ASC-H appears to be associated with an
increased risk of clinically signiﬁcant lesions, especially when
associated with oncogenic HPV. Excision of the lesion may
be indicated because the risk for histologic CIN II found was
high for women with HPV positive tests, HSIL cytology, and
a high-grade impression at colposcopy [33]. Other methods
as liquid-based cervical cytology do not show more eﬃcacies
in diagnosis HSIL compared to Pap smears [34]. Actually,
the frontiers of cervical cancer prevention is the preventing
persistent HPV infections using vaccination or HPV testing
utilizing opportunistic or organized screening [35].
We believe thatthe data obtained in this study provide an
important conﬁrmation of the usefulness of both the ASCUS
subdivision according to the Bethesda 2001 protocol and the
hybrid capture test. We propose that an initial cytology of
ASC-US be reviewed for diagnostic conﬁrmation and that,
if it stands, two strategies should be followed: (1) an HPV
test should be performed, and (2) if there is a positive high-
risk HPV ﬁnding, there should be a colposcopy or semi-
annual followup with cytology. In cases classiﬁed as normal
after a review of the ASC-US diagnosis, we suggest a new
cytology be performed after 6 months. This ﬁnding is in
agreement with the data obtained by Chen et al. [36], whose
ﬁndings also lead to the conclusion that a cytology of ASC-
US, especially without a prior Pap smear, is quite likely to
develop into cervical cancer and that of the most aggressive
kind. Another study about ASC-H showed that HPV DNA
testing has an extremely high negative predictive value for
histologic CIN II/III, reaching 100% in women 40 years and
older[37].Basedon2006consensusguidelines,aprogramof
DNA testing for high-risk types of HPV, repeat cervical cyto-
logic testing, or colposcopy are all acceptable methods for
managingwomenovertheageof20yearswithASC-US[38].
This study allows us to conclude that the level of agree-
ment between observers in diagnosing ASCUS upon review
was 67.96%. The frequency of infection was higher in
patients with ASC-US than in patients in the ASC-H group,
and the frequency of abnormal colposcopic ﬁndings was
greater in the neoplastic ASCUS and ASC-H groups than
in the reactive ASCUS and ASC-US groups, respectively. A
positive HPV test, used in the triage of patients with ASC-US
for colposcopy indication, appears to be associated with an
increased chance of detecting CIN.
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